-
-
-
-
-
-
-
Vanda launches motion sickness drug NEREUS after 40-year gap
-
-
-
-
-
-
-
FDA accepts Vanda's drug application for rare skin disorder treatment
-
-
-
-
-
-
-
FDA rejects Vanda's HETLIOZ application for jet lag disorder
-
-
-
-
-
-
-
FDA lifts clinical hold on Vanda's motion sickness drug tradipitant
-
-
-
-
-
-
-
Vanda Pharmaceuticals reaches dispute resolution framework with FDA
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Vanda Pharmaceuticals (VNDA)
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
-
425,763 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

